Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 23-May-2013
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 4 of 4)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
18-May-13Reuters Investment ProfileN/AThrombogenics NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.12$138  View Abstract
17-May-13Wright ReportsN/AWright Investors Service Comprehensive Report for Thrombogenics Nv40$460  View Abstract
7-May-13GlobalDataGlobalDataThromboGenics NV (THR) - Financial and Strategic SWOT Analysis Review40$125  View Abstract
8-Apr-13GlobalDataGlobalDataThromboGenics NV (THR) - Financial and Strategic SWOT Analysis Review39$125  View Abstract
Independent Reports (Showing 1 to 4 of 4)
Release
Date [down]		 Contributor Author Title Pages Price More Info
18-May-13Reuters Investment ProfileN/AThrombogenics NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.12$138View Abstract
17-May-13Wright ReportsN/AWright Investors Service Comprehensive Report for Thrombogenics Nv40$460View Abstract
7-May-13GlobalDataGlobalDataThromboGenics NV (THR) - Financial and Strategic SWOT Analysis Review40$125View Abstract
8-Apr-13GlobalDataGlobalDataThromboGenics NV (THR) - Financial and Strategic SWOT Analysis Review39$125View Abstract

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.